Avelox

Avelox is a brand name of moxifloxacin, approved by the FDA in the following formulation(s):

AVELOX (moxifloxacin hydrochloride - tablet; oral)

• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: December 10, 1999
  
  Strength(s): EQ 400MG BASE ^[RLD]

Has a generic version of Avelox been approved?

No. There is currently no therapeutically equivalent version of Avelox available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avelox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  7-(1-pyrrolidinyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives as antibacterial agents and feed additives
  Patent 4,990,517
  Issued: February 5, 1991
  Inventor(s): Petersen; Uwe & Schenke; Thomas & Krebs; Andreas & Grohe; Klaus & Schriewer; Michael & Haller; Ingo & Metzger; Karl G. & Endermann; Rainer & Zeiler; Hans-Joachim
  Assignee(s): Bayer Aktiengesellschaft
  7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives as antibacterial agents and feed additives, of the formula ##STR1## in which X.sup.1 is halogen, X.sup.2 is hydrogen, halogen, amino or other radical, R.sup.1 is alkyl, cycloalkyl, optionally substituted phenyl or other radical, R.sup.2 is hydrogen, alkyl or a dioxolylmethyl radical, R.sup.3 is ##STR2## A is N, CH, C-halogen, or the like, or forms a bridge with R.sup.1, and addition products thereof.
  
  Patent expiration dates:
  
  
  • December 8, 2011
    
    ✓ 
    Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
  Patent 5,607,942
  Issued: March 4, 1997
  Inventor(s): Petersen; Uwe & Schenke; Thomas & Krebs; Andreas & Grohe; Klaus & Schriewer; Michael & Haller; Ingo & Metzger; Karl G. & Endermann; Rainer & Zeiler; Hans-Joachim
  Assignee(s): Bayer Aktiengesellschaft
  7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives, of the formula ##STR1## in which X.sup.1 is halogen, X.sup.2 is hydrogen, halogen, amino or other radical, R.sup.1 is alkyl, cycloalkyl, optionally substituted phenyl or other radical, R.sup.2 is hydrogen, alkyl or a dioxolylmethyl radical, R.sup.3 is ##STR2## and A is N, CH, C-halogen, or the like, or forms a bridge with R.sup.1, and addition products thereof.
  
  Patent expiration dates:
  
  
  • March 4, 2014
    
    ✓ 
    Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
  
  



• 
  Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification
  Patent 5,849,752
  Issued: December 15, 1998
  Inventor(s): Grunenberg; Alfons & Bosche; Patrick
  Assignee(s): Bayer Aktiengesellschaft
  The invention relates to the new monohydrate of 1-cyclopropyl-7-(›S,S!-2,8-diazabicyclo-›4.3.0!non-8-yl)6-fluoro-1,4-dihyd ro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride (CDCH), a process for its preparation and pharmaceutical formulations which comprise this monohydrate as the active compound.
  
  Patent expiration dates:
  
  
  • December 5, 2016
    
    ✓ 
    Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
  
  



• 
  Pharmaceutical moxifloxacin preparation
  Patent 6,610,327
  Issued: August 26, 2003
  Inventor(s): Patrick; Bosché & Hans Friedrich; Mahler & Claus; Weisemann
  Assignee(s): Bayer Aktiengesellschaft
  The present invention relates to a pharmaceutical preparation for oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the use of this preparation for controlling bacterial infections in humans and animals.
  
  Patent expiration dates:
  
  
  • October 29, 2019
    
    ✓ 
    Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
    ✓ 
    Drug product
  
  

See also...

• Avelox Consumer Information (Drugs.com)
• Avelox Consumer Information (Wolters Kluwer)
• Avelox Tablets Consumer Information (Wolters Kluwer)
• Avelox Consumer Information (Cerner Multum)
• Avelox Advanced Consumer Information (Micromedex)
• Avelox AHFS DI Monographs (ASHP)
• Moxifloxacin Consumer Information (Wolters Kluwer)
• Moxifloxacin Tablets Consumer Information (Wolters Kluwer)
• Moxifloxacin Consumer Information (Cerner Multum)
• Moxifloxacin Advanced Consumer Information (Micromedex)
• Moxifloxacin Intravenous Advanced Consumer Information (Micromedex)
• Moxifloxacin Hydrochloride AHFS DI Monographs (ASHP)